In the United States, LDL apheresis is approved for homozygous familial hypercholestrolemia (FH) patients with an LDL cholesterol level ≥ 500 mg/dL. For patients with heterozygous FH, LDL apheresis may be offered if their LDL is ≥ 300 mg/dL, or ≥ 200 mg/dL with known coronary artery disease, despite maximum medical treatment. The available LDL apheresis methods differ with respect to acute relative reductions of LDL cholesterol; mean values after the LDL apheresis treatments are not different. Serum triglycerides, HDL-cholesterol, and lipoprotein(a) are also acutely reduced. Cardiovascular events are clearly reduced by the LDL apheresis methods.
Satoshi Morimoto Efficacy of Low-Density Lipoprotein Apheresis in Patients with Peripheral Arterial Occlusive Disease Undergoing Hemodialysis Treatment Nephrology Vol. 27, No. 6, 2007
Puja K. Mehta, Jefferson Baer, Christine Nell and Laurence S. Sperling Low-density lipoprotein apheresis as a treatment option for hyperlipidemia
Journal Current Treatment Options in Cardiovascular Medicine
Volume 11, Number 4 / August, 2009
Pages 279-288, July 14, 2009
Julius U, Frind A, Tselmin S, Kopprasch S, Poberschin I, Siegert G.Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther. 2008 Jun;6(5):629-39.